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SYNOPSIS: In an attempt to clarify the effect of amantadine hydro-
chloride therapy in Parkinson's disease, dopa metabolites were 
measured in the urine of 15 patients who were taking this medica-
tion. The results indicated that patients on amantadine therapy 
Since Schwab and colleagues ( 1969) have reported on 
the use of amantadine hydrochloride in the treatment of 
Parkinson's disease the drug has been investigated by many 
others, most of whom have found it useful. Unlike the many 
biochemical studies done on parkinsonian patients on levo-
dopa therapy, little has been reported on biochemical changes 
in the serum, spinal fluid and urine of patients treated with 
amantadine hydrochloride. The action of this drug is not well 
understood at present but there are several theories as to its 
possible mode of action. Grelak and associates ( 1970) sug-
gested that the mechanism of action of amantadine may be 
by the release of catecholamines from storage sites. Parkes 
et al. (1971) indicated that the mode of action of amanta-
dine remains undetermined but they demonstrated that it 
does not increase the low cerebrospinal fluid homovanillic 
acid concentrations of patients with Parkinson's disease. 
Amantadine hydrochloride has little or no anticholinergic ac-
tion, but will release catecholamines from storage sites in 
peripheral nerves and myocardium ( 1969). Scatton et al. 
( 1970) demonstrated that amantadine increased the synthe-
sis of dopamine in the striatum of the rat, also increased the 
release of dopamine from the striatal dopaminergic terminals 
in this animal. Livedo reticularis is a well-known side effect 
associated with amantadine therapy in parkinsonian patients. 
This condition probably results from peripheral arterial con-
striction; there is some evidence that amantadine may release 
dopamine or some other dopa metabolite ( 1971). In an at-
tempt to clarify the effect of amantadine hydrochloride in 
Parkinson's disease, dopa metabolites were measured in the 
urine of patients who were taking this medication. Particular 
attention was paid to those who developed livedo reticularis. 
MATERIALS AND METHODS 
Ten patients with Parkinson's disease were evaluated in a 
l Departments of Neurology and Biochemistry, University of 
Iowa Hospitals, Iowa City, Iowa 52242. 
had lower urinary levels of epinephrine plus norepinephrine than 
either normal individuals or parkinsonian patients not receiving 
amantadine. Patients who developed livedo reticularis during 
amantadine therapy showed a small but significant increase in 
urinary dopamine levels and a similar decrease in dopac levels, 
when compared to other patients on amantadine who did not 
develop livedo reticularis. 
double-blind double-crossover study in which the patients al-
ternately received either placebo or amantadine hydrochlor-
ide. At the end of the two week period of administration of 
placebo or amantadine hydrochloride a 24-hour urine speci-
men was collected. Twenty-four-hour specimens were also 
collected from seven patients who developed livedo reticu-
laris in their extremities while undergoing amantadine ther-
apy; these specimens were collected both during the height 
of symptoms and later after amantadine had been discon-
tinued for at least two weeks and the symptoms of livedo 
reticularis had been absent for at least one week. For both 
groups of patients at least one urine determination was made 
while the patient was on amantadine and one urine determin-
ation while either on no medication or on placebo. The urine 
was evaluated for epinephrine, norepinephrine, dopamine, 
dopa, dopac, and homovanillic acid. These compounds were 
separated from the urine and from each other by passing an 
aliquot of each specimen through a series of three different 
ion-exchange columns. Catecholamines (epinephrine, norep-
inephrine and dopamine) were retained on a cation ex-
change column. These compounds were eluted with a boric 
acid solution and quantitatively measured by a fluorimetric 
analysis. Catechol acids ( dopac and homovanillic acid) pres-
ent in the effluent from the cation exchange column were 
retained on an anion exchange column. An aliquot of 0.lM 
NaCl eluate of the anion exchange column was used for a 
colorimetric determination of dopac. The colorimetric de-
termination of dopa was carried out on an aliquot of the ef-
fluent from the anion exchange column. A second aliquot of 
the O.lM NaCl eluate from this column was passed over an 
alumina column which retained all of the acidic metabolites 
except homovanillic acid. The homovanillic acid in the efflu-
ent of the alumina column was then subjected to fluorimetric 
analysis. The ion-exchange column separation scheme and 
the detailed quantitative methodology is being reported in 
a separate communication ( 1971). 
Normal values have been established in this laboratory as 
follows: epinephrine plus norepinephrine: 0.04 to 0.08 p.g/ 
ml; dopac: 2-5 p.g/ml; dopamine: 0.2 to 0.3 p.g/ml; and 
dopa: less than 2.0 µ.g/ml. 
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RESULTS 
A total of 15 patients were evaluate:! for urine dopa me-
tabolites. All 15 were grouped together; these data were 
evaluated and compared with respect to the patients being 
on and off medication and as to whether they did or did not 
develop livedo reticularis. 
It was found that the range of values of the metabolites in 
normal individuals was too broad to detect meaningful in-
creases or decreases in these substances in the urine speci-
mens from patients. In general, patients with Parkinson's 
disease exhibited elevated levels of dopac, dopamine, and 
dopa in their urine. Patients on amantadine therapy excreted 
lower levels of epinephrine plus norepinephrine than normal 
individuals. When patients who developed livedo reticularis 
were compared with those who did not develop symptoms, 
no changes in the excretion of the metabolites were observed. 
Homovanillic acid excretion was similar in patients and nor-
mal individuals. 
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In a further attempt to assess the data, the values of the 
excreted metabolites from the fifteen patients were subjected 
to statistical analysis. The mean value of each metabolite was 
calculated and compared for patients on placebo as well as 
for patients on amantadine hydrochloride therapy. Means or 
averages are plotted with confidence intervals on graphs in 
Figure 1, for four of the measured urine catecholamines and 
separated into non-livedo and livedo patients. The norepin-
ephrine plus epinephrine values differed significantly between 
the placebo and the amantadine data, indicating less nor-
epinephrine plus epinephrine in the urine of patients while 
on amantadine HCl (using a "p" value less than 0.01). This 
can be seen in the graph for norepinephrine plus epinephrine. 
The patients were also grouped into those who did and who 
did not develop livedo reticularis while on amantadine. From 
the graph no significant difference is noted for the epin-
ephrine plus norepinephrine or dopa in these comparisons. The 
most significant difference is noted in the means for dopac, 
where patients who devebped livedo reticularis while on 
amantadine had a significant decrease in the level of dopac 
in the urine ("p" value = 0.05). Also, there was a decrease 
of dopac in the urine of all livedo reticularis patients whether 
they were on or off amantadine; this also is significant at the 
5 percent level. Patients with livedo reticularis on or off 
amantadine had higher levels of dopamine ("p" value = 
0.05). 
CONCLUSIONS 
The results indicate that patients receivmg amantadine 
hydrochloride excreted less norepinephrine plus epinephrine 
in the urine than when they were not taking the drug. The 
livedo reticularis patients either on or off the medication ex-
creted less dopac and more dopamine as compared to the 
non-livedo reticularis patients. 
From the above data there is no direct evidence of the 
release of catecholamines by amantadine hydrochloride as 
measured in the urine. On the other hand, there is less nor-
epinephrine and epineph1ine in the urine during amantadine 
administration. The significance of the decreased dopac and 
the increased dopamine levels in the urine in patients who 
develop livedo reticularis is unknown. Patients who did de-
velop livedo reticularis had a lower creatinine clearance than 
patients who did not develop the skin disorder. In the park-
insonian patient one might postulate amantadine hydrochlor-
ide increases the physiological availability of dopamine by 
increasing the synthesis of and/ or release of dopamine in or 
from the dopaminergic neurons and thus enhances its effec-
tiveness as a neurotransmitter. This would be consistent with 
the finding of decreased levels of end metabolites such as 
norepinephrine and epinephrine. This increased synthesis 
and/ or increased release of dopamine by amantadine hydro-
chloride has been demonstrated by Scatton and associates 
( 1970). One hypothesis for the increased synthesis of dopa-
mine would be some physiological enhancement or increased 
synthesis of tyrosine hydroxylase ( 1971). From our data there 
is little or no supp:Jrt for the concept that amantadine hydro-
chloride acts to block a metabolic pathway especially from 
dopamine to dopac or dopamine to norepinephrine, since no 
elevated levels of dopamine were detectable in the urine 
when the patient was receiving amantadine. Amantadine 
hydrochloride also probably does not act as a false neuro-
transmitter, since we have some data to support the concept 
that there is a change in the metabolic pathways because of 
decreased epinephrine and norepinephrine in the urines of 
patients receiving amantadine. This theory would also ex-
plain the development of livedo reticularis since dopamine 
is a vasoconstrictor, acts on alpha receptors and could pro-
duce vasoconstriction in the arteriole of the anatomical cone 
in the skin to result in a central ischemic area with the per-
ipheral vasodilation. This is the typical fishnet-like appear-
ance of livedo reticularis. Further studies need to be carried 
out on dopa metabolites in the urine, spinal fluid and serum 
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in patients rece1vmg amantadine, using proper controls, es-
pecially in patients who do not develop livedo reticularis. 
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